am -
pm ET,

How Alnylam Assist® Can Help

Alnylam Assist® will be there for your patients.

Ready to enroll your patient?

Get Started Here

Access and Reimbursement

  • Benefit verification
  • Education about the prior authorizations, claims, and appeals processes


Additional Support

  • Disease and product education
  • Benefit explanation
  • Continued communication customized to each patient's preferences

Financial Assistance Programs*

  • Your patients may qualify for:
  • Quick Start Program
  • Patient Assistance Program (PAP)
  • Commercial Copay Program

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.


Download Brochures & Guides

Alnylam Assist® Services Overview Brochure

Alnylam Assist® Services Overview Brochure for HCPs thumbnail



Alnylam Assist® Brochure

Alnylam Assist® Brochure for Patients thumbnail


Discover More

Enroll Your Patients

Ready to begin the Start Form?

Get Started


Find answers to frequently 
asked questions here.

Get Answers

Alnylam Assist® - Support Team

Take Action Now

Together with your patient (in office)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).


ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.